1.Hunan, Jiangxi, Guangdong, Hong Kong and Macao explore a new path for high-quality development of traditional Chinese medicine
On the 18th, the unveiling ceremony of the Hunan Jiangxi Guangdong Hong Kong Macao TCM Whole Industry Chain Collaborative Development Alliance (hereinafter referred to as the “Alliance”) was held in Hunan University of Traditional Chinese Medicine.
On November 16 this year, with the support of the CPPCC National Committee, the State Administration of Traditional Chinese Medicine, the CPPCC Hunan, Jiangxi and Guangdong Provinces and relevant departments in Hong Kong and Macao, the Alliance was officially established.
At the unveiling ceremony, Liu Liang, the chairman of the Alliance and an academician of the CAE Member, together with the main heads of the Hong Kong, Macao, Taiwan, Overseas Chinese and Foreign Affairs Committee of the CPPCC Hunan Provincial Committee, the Provincial Administration of Traditional Chinese Medicine, Hunan University of Traditional Chinese Medicine and other units, unveiled the plaque for the Alliance Secretariat, and awarded the plaque for the Alliance Chinese Medicine Cooperation Center, Chinese Medicine Science and Technology Innovation Cooperation Center, Chinese Medicine Industrialization Cooperation Center, and Chinese Medicine Trade Cooperation Center.
The establishment of the four centers marks the first step in the construction of the whole industrial chain of “science, agriculture, industry, trade and medicine” promoted by the Alliance, and the substantial operation. The four centers will use science and technology to deconstruct traditional Chinese medicine, deeply explore the core technology of traditional Chinese medicine, expand the upstream, radiate the downstream, form a closed loop, improve quality and efficiency, give full play to the maximum potential of the upstream and downstream links of the three provinces and two regions, truly realize chain linking, chain supplement and chain strengthening, and ensure a qualitative leap in the coordinated development of the regional industrial chain.
2.Raise the price of epidemic related materials, with a maximum increase of more than 600%! Strict investigation!
In view of the recent abnormal price fluctuations in the market of epidemic related materials, Zhejiang Provincial Market Supervision and Administration Bureau strengthened the supervision and enforcement of the price of epidemic related medical drugs, antigen testing reagents, and protective articles, carried out online and offline inspections, concentrated on finding and removing illegal clues to bid up the price, and investigated and dealt with strictly and quickly according to law, and announced the first nine typical cases of bid up the price of epidemic related materials on the evening of the 16th.
On December 8, the law enforcement personnel of Nanxun District Market Supervision Bureau in Huzhou City, Zhejiang Province found that a clinic of integrated traditional and western medicine uploaded a video on the Tiktok platform, spreading the information that the price of epidemic drugs such as Lianhua Qingwen was about to rise significantly. On the same day, the on-site inspection found that he posted a notice in the diagnosis and treatment service area, saying that “due to limited inventory and difficulty in purchasing, the price of four epidemic related drugs, Lianhua Qingwen, Shuanghuanglian Oral Liquid, WeiC Yinqiao Tablets and Banlangen Granules, will rise from December 10″.
The relevant person in charge of Nanxun District Market Supervision Bureau said that the clinic used Tiktok and posting notices in the diagnosis and treatment service area to spread information about price increases, attract consumers to come to buy, further raise price expectations, which is suspected to constitute an illegal act of driving up prices. Nanxun District Market Supervision Bureau has filed an investigation on December 9 and will make a decision on administrative punishment in the near future.
3.The third dose of COVID-19 vaccine in Japan accounts for 67.4% of the total population
The latest data released by the Japanese government on the 19th showed that the number of people who completed the third dose of COVID-19 vaccine in Japan was 84911922, accounting for 67.4% of the total population.
The data shows that the number of people who have completed the first dose of COVID-19 vaccine in Japan accounts for 81.4% of the total population of the country; The number of people who completed the second vaccination accounted for 80.4% of the total population. It is reported that Japan began to vaccinate COVID-19 vaccine against the variant strain of Omikjon in September this year, targeting people aged 12 and above who have received at least two doses of vaccine. According to the data, 37582513 people were vaccinated with COVID-19 vaccine against the variant strain of Omikjon, accounting for 29.8% of the total population of the country.
According to the Japanese Broadcasting Association TV reported on the 18th, due to the expansion of COVID-19 infection, the demand for fever and pain relievers is growing, and some medical institutions and pharmacies in Japan are short of fever and pain relievers. In this regard, the Ministry of Health, Labor and Welfare of Japan opened special windows for hospitals receiving patients with COVID-19 and pharmacies providing prescription drugs to help relevant institutions purchase drugs from suppliers with sufficient reserves. In addition, the Ministry of Health, Labor and Welfare also entrusted drug wholesale enterprises to give priority to smaller pharmacies.
According to the statistics of the Ministry of Health, Labor and Welfare of Japan, 70921 new confirmed cases were confirmed in Japan on the 19th, with a total of 27187394 confirmed cases; There were 180 new deaths, and the cumulative number of deaths exceeded 53499. There were 7949 newly confirmed cases in Tokyo on the same day, and the new cases in a single day have exceeded the same period of the previous week for 14 consecutive days.
JinDun Medical has long-term scientific research cooperation and technology grafting with Chinese universities. With Jiangsu’s rich medical resources, it has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets. It also provides market and sales services in the whole process from intermediate to finished product API. Utilize the accumulated resources of Yangshi Chemical in fluorine chemistry to provide special chemical customization services for partners. Provide process innovation and impurity research services to target customers.
JinDun Medical insists on creating a team with dreams, making products with dignity, meticulous, rigorous, and go all out to be a trusted partner and friend of customers!One stop solution providers, customized R&D and customized production services for pharmaceutical intermediates and APIs, professional customized pharmaceutical production (CMO) and customized pharmaceutical R&D and production (CDMO) service providers. Jindun will accompany you to spend COVID-19.
Post time: Dec-23-2022